{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:46Z","timestamp":1786985266206,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.biopha.2024.116485","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:55:03Z","timestamp":1711083303000},"page":"116485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies"],"prefix":"10.1016","volume":"174","author":[{"given":"Peng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.biopha.2024.116485_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMc1710026","article-title":"Health effects of overweight and obesity in 195 countries","volume":"377","author":"Ortega","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116485_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0140-6736(13)61836-X","article-title":"Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants","volume":"383","author":"Yuan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116485_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Katherine","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2024.116485_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2024.116485_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.biopha.2024.116485_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol. Rev."},{"issue":"21","key":"10.1016\/j.biopha.2024.116485_bib7","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116485_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"7680","key":"10.1016\/j.biopha.2024.116485_bib9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(70)92126-4","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover Duncan LJ, Treatment of hypoglyc\u00e6mic coma with glucagon, intravenous dextrose, and mannitol infusion in a hundred diabetics","volume":"2","author":"Maccuish","year":"1970","journal-title":"Lancet"},{"issue":"1 Part 1","key":"10.1016\/j.biopha.2024.116485_bib10","first-page":"74","article-title":"The effect of glucagon on the blood glucose level and the clinical state in the presence of marked insulin hypoglycemia","volume":"36","author":"Greben","year":"1957","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.biopha.2024.116485_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biopha.2024.116485_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the Balance: GLP-1\/Glucagon Co-Agonism as a Treatment Strategy for Obesity","author":"Hope","year":"2021","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.biopha.2024.116485_bib13","unstructured":"Altimmune Announces Positive Results From Week 24 Interim Analysis Of Pemvidutide MOMENTUM Phase 2 Obesity Trial And 12-Week Phase 1b Type 2 Diabetes Safety Trial, https:\/\/ir.altimmune.com\/news-releases\/news-release-details\/altimmune-announces-positive-results-week-24-interim-analysis."},{"issue":"2","key":"10.1016\/j.biopha.2024.116485_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12433","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study","volume":"11","author":"Di Prospero","year":"2021","journal-title":"Clin. Obes."},{"issue":"3","key":"10.1016\/j.biopha.2024.116485_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116485_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.116485_bib17","article-title":"Perspectives in weight control in diabetes - BI 456906","author":"Klein","year":"2023","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.biopha.2024.116485_bib18","unstructured":"Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis. https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/survodutide-top-line-results-mash-fibrosis."},{"key":"10.1016\/j.biopha.2024.116485_bib19","doi-asserted-by":"crossref","DOI":"10.2337\/db19-982-P","article-title":"A double-blinded, placebo controlled, single ascending dose study for safety, tolerability, pharmacokinetics, and pharmacodynamics after subcutaneous administration of novel long-acting GLP-1\/GIP\/glucagon triple agonist (HM15211) in healthy obese subjects","volume":"68","author":"Choi","year":"2019","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.biopha.2024.116485_bib20","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1111\/dom.15235","article-title":"Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists","volume":"25","author":"Jiang","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.116485_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264974","article-title":"Preclinical evaluation of a protracted GLP-1\/glucagon receptor co-agonist: Translational difficulties and pitfalls","volume":"17","author":"Simonsen","year":"2022","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.biopha.2024.116485_bib22","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3390\/ijms20163905","article-title":"Glucagon Control on Food Intake and Energy Balance","volume":"20","author":"Al-Massadi","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116485_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1677\/joe.0.1710293","article-title":"Insulin resistance in obesity: body-weight or energy balance","volume":"171","author":"Assali","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116485_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00125-011-2065-0","article-title":"Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide","volume":"54","author":"Dub\u00e9","year":"2011","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.biopha.2024.116485_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.31","article-title":"Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history","volume":"7","author":"Clamp","year":"2017","journal-title":"Nutr. Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2024.116485_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/ajcn\/87.5.1141","article-title":"Effect of a dietary-induced weight loss on liver enzymes in obese subjects","volume":"87","author":"Gasteyger","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.biopha.2024.116485_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2024.116485_bib28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 diabetes: a 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116485_bib29","unstructured":"A 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-alcoholic Fatty Liver Disease (NAFLD). https:\/\/ir.altimmune.com\/static-files\/f4e33c4a-8c4e-42e4-aaec-7418e82fc0d6."},{"issue":"4","key":"10.1016\/j.biopha.2024.116485_bib30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116485_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modifcation signifcantly reduces features of nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2024.116485_bib32","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of\u2265 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.116485_bib33","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116485_bib34","first-page":"2396","article-title":"Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect","volume":"20","author":"Iorga","year":"2020","journal-title":"Exp. Ther. Med"},{"issue":"24","key":"10.1016\/j.biopha.2024.116485_bib35","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Hovingh","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.biopha.2024.116485_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.biopha.2024.116485_bib37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2024.116485_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.116485_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000439083","article-title":"Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: is there a relationship","volume":"92","author":"Abdelaziz","year":"2015","journal-title":"Digestion"},{"issue":"11","key":"10.1016\/j.biopha.2024.116485_bib40","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/metabo13111115","article-title":"Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease","volume":"13","author":"G\u00eelc\u0103-Blanariu","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.biopha.2024.116485_bib42","unstructured":"A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects. https:\/\/classic.clinicaltrials.gov\/ProvidedDocs\/92\/NCT03486392\/Prot_000.pdf."},{"issue":"8","key":"10.1016\/j.biopha.2024.116485_bib43","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/dom.14394","article-title":"Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide","volume":"23","author":"Schiavon","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2024.116485_bib44","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.3390\/ijms24044029","article-title":"Novel molecules in diabetes mellitus, dyslipidemia and cardiovascular disease","volume":"24","author":"Vesa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2024.116485_bib45","doi-asserted-by":"crossref","first-page":"14631","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: A Systematic Update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J. Mol. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400369X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400369X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:52:08Z","timestamp":1782341528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222400369X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S075333222400369X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116485","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116485"}}